Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Salarius Pharmaceuticals, LLC
- Target Recruit Count
- 72
- Registration Number
- NCT05979857
A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Salarius Pharmaceuticals, LLC
- Target Recruit Count
- 10
- Registration Number
- NCT05266196
- Locations
- ๐บ๐ธ
Sarcoma Oncology Center, Santa Monica, California, United States
Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors
- First Posted Date
- 2019-03-29
- Last Posted Date
- 2021-10-18
- Lead Sponsor
- Salarius Pharmaceuticals, LLC
- Target Recruit Count
- 23
- Registration Number
- NCT03895684
- Locations
- ๐บ๐ธ
Sarcoma Oncology Research Center, Santa Monica, California, United States
๐บ๐ธHonorHealth, Scottsdale, Arizona, United States
Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Salarius Pharmaceuticals, LLC
- Target Recruit Count
- 50
- Registration Number
- NCT03600649
- Locations
- ๐บ๐ธ
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
๐บ๐ธDana-Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธSarcoma Oncology Research Center, Santa Monica, California, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath